Thrombin induces platelet aggregation and formation of a fibrin clot in platelet-rich plasma; leupeptin, a protease inhibitor, partially inhibits platelet aggregation, but it does not inhibit fibrin clot formation. Indomethacin does not inhibit either thrombin-induced platelet aggregation or fibrin clot formation. However, when the two drugs are given together, a synergistic inhibition of thrombin-induced platelet aggregation occurs, while fibrin clot formation remains unaffected. Thrombin-induced stimulation of the release of serotonin in washed human platelets is also synergistically inhibited by the combined actions of leupeptin and indomethacin. Thrombin and collagen, added simultaneously, induce full platelet aggregation and release of serotonin. Neither leupeptin nor indomethacin inhibits platelet responses elicited by both agonists; however, when leupeptin and indomethacin are given together, a synergistic inhibition of thrombin-and collageninduced response is observed. These findings might be relevant in prophylaxis and treatment of thromboembolic disease.
Antiplatelet drugs-aspirin, dipyridamole, and sulfinpyrazone-have been shown to inhibit thrombus formation in experimental animal models, presumably by preventing platelet activation at sites of vascular injury. Several clinical trials have tested the effectiveness ofthese drugs in situations where platelet phenomena and thrombus formation may play an important role in the pathogenesis of certain clinical disorders-e.g., stroke and myocardial infarction (1) (2) (3) (4) (5) .
The overall results, however, have been equivocal. This has been attributed to the inhibition of vascular prostacyclin biosynthesis coincident with that of thromboxane A2 by the doses of cyclooxygenase inhibitors used in many clinical trials (5) (6) (7) and to the inability of cyclooxygenase inhibitors to inhibit thrombin-induced platelet activation (1) .
We have recently shown that leupeptin, a protease inhibitor, is able to block human platelet responses to thrombin and trypsin, while it does not inhibit serotonin release and aggregation induced by collagen (8) . We (10 ,ug/ml) and/or indomethacin (10-20 ,uM) for 1 min was followed by the addition of thrombin (0.5 unit/ml). Light transmission was recorded throughout the experiment and displayed on a chart recorder.
To obtain washed platelets, platelet-rich plasma was centrifuged at 200 x g for 15 min. This platelet pellet was resuspended in 10 ml of a modified Tyrode-Hepes buffer (134 mM NaCl/12 mM NaHCO3/2.9 mM KCl/0.36 mM NaH2PO4/1 mM MgCl2/5 mM Hepes/5 mM glucose, pH 7.4), and 10 ml of the platelet suspension was labeled with 50 ,Ci ( 
RESULTS
Effect of Leupeptin and Indomethacin on Thrombin-Induced Platelet Aggregation in Platelet-Rich Plasma. Thrombin (0.5 unit/ml) induced platelet shape change and aggregation in platelet-rich plasma, as shown in Fig. 1A by a gradual increase in light transmission. After 30-35 sec, however, an abrupt decrease oflight transmission in the recorder reflected formation of a fibrin clot. Leupeptin (10 ,g/ml), added 1 min before thrombin (0.5 unit/ml), partially inhibited thrombin-*On leave from the Istituto di Patologia Generale, Universita degli Studi di Firenze, Firenze, Italy. tTo whom reprints requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. . Thrombin (0.5 unit/ml) was then added (arrow labeled "T"); light transmission was recorded throughout the experiment to determine the extent of platelet aggregation (revealed by a gradual increase in light transmission) and the formation of a fibrin clot (revealed by an abrupt decrease in light transmission followed by a rapid increase).
induced platelet aggregation, but it did not inhibit fibrin clot formation (Fig. 1B) . Indomethacin (up to 20 AM) added 1 min before thrombin (0.5 unit/ml) did not inhibit either platelet aggregation or fibrin clot formation (Fig. 1C) . However, when leupeptin (10 ,ug/ml) and indomethacin (10 ,M) were given together 1 min before thrombin (0.5 unit/ml), platelet aggregation was completely inhibited, while fibrin clot formation was unaffected (Fig. 1D) .
Effect of Leupeptin and Indomethacin on Thrombin-Induced Serotonin Release in Washed Human Platelets. Thrombin (0.3 unit/ml) induced the release of approximately 95% of
[3H]serotonin in washed human platelets (Fig. 2) . Leupeptin (0.5-20 ,ug/ml) added 1 min before thrombin (0.3 unit/ml) inhibited thrombin-induced serotonin release, and maximal inhibition occurred with leupeptin at 20 ,ug/ml (Fig. 2) . Indomethacin (1 ,M) added 1 min before thrombin (0.3 unit/ml) inhibited 45% of thrombin-induced serotonin release (Fig. 2) . However, when both inhibitors were given together 1 min before thrombin, full inhibition of serotonin release occurred with leupeptin at only 2.5 ,ug/ml. This significant shift to lower concentrations of leupeptin for nearly total suppression of activity clearly demonstrates a synergistic pattern of inhibition (Fig. 2) .
Effect of Leupeptin and Indomethacin on Thrombin/Collagen-Induced Aggregation in Washed Human Platelets. Simultaneous addition of thrombin (0.3 unit/ml) and collagen (20 ,g/ml) induced maximal aggregation in washed human platelet (Fig. 3A) . Leupeptin (up to 20 ,g/ml) added 1 min before the thrombin and collagen did not inhibit platelet aggregation induced by both agonists (Fig. 3B) . Similarly, indomethacin (up to 20 ,M) added 1 min before thrombin and collagen did not inhibit platelet aggregation induced by both agonists ( 
3D, E, andF).
Effect of Leupeptin and Indomethacin on Thrombin/Collagen-Induced Serotonin Release in Washed Human Platelets. Simultaneous addition of thrombin (0.3 unit/ml) and collagen (20 pug/ml) induced the release of approximately 98% of [3H]serotonin'in washed human platelets (Fig. 4) . Leupeptin did not inhibit significantly the release of serotonin induced by both agonists (Fig. 4) . Similarly, indomethacin (5-10 ,M) added 1 min before thrombin and collagen only partially inhibited the release of serotonin induced by both agonists (Fig. 4) . However, when leupeptin (0.5-20 gg/ml) and indomethacin (5) (6) (7) (8) (9) (10) gM) were given together 1 min before thrombin and collagen, a dramatic synergistic inhibition of the effect of both agonists was evident (Fig. 4) .
DISCUSSION
This study demonstrates that leupeptin-a protease inhibitor-plus indomethacin-a cyclooxygenase inhibitor-synergistically inhibit the effect of thrombin and thrombin/ collagen on human platelets.
Leupeptin inhibits all platelet responses elicited by thrombin and trypsin (8) , although it does not inhibit thrombin's proteolytic activity or its binding to the platelet surface (9) (10) (11) . However, leupeptin does not inhibit platelet activation induced by collagen, which is another Felevant platelet physiological agonist (8) . Indomethacin effectively inhibits collagen-induced platelet activation, but it does not completely inhibit the effect of thrombin on platelets (1) . This study demonstrates that a combination of leupeptin and indomethacin effectively inhibits platelet activation induced by both agonists. When both drags are administered together, full platelet inhibition' occurs at doses that are unable to prevent platelet activation when each inhibitor is used alone.
The effects ofindomethacin and leupeptin can be explained on the basis of inhibition of platelet cyclooxygenase and proteolysis, respectively. Indomethacin inhibits cyclooxygenase, which catalyzes the formation of endoperoxides and thromboxane A2. On the other hand, proteases play a role in platelet aggregation and, accordingly, different protease inhibitors and substrates have been tested for their inhibitory activity on platelet aggregation (12) . Recently, it has been shown that a platelet Ca2+-dependent protease is activated during aggregation (13) , and two specific proteins are hydrolyzed (14, 15) . Ca2+-dependent proteolysis has been proposed to play a role in agonist-induced expression of fibrinogen receptor (9) , in the irreversible activation of protein kinase C (16) , and in the regulation of platelet phospholipases (8) . In all of these processes in which Ca2+-dependent proteolysis might be involved, leupeptin is an effective inhibitor (8, 9, 13-15).
In recent years nonsteroidal antiinflammatory drugs such as aspirin and sulfinpyrazone have been used to treat cerebral ischemia and cardiovascular disease (2, 3) . There has been a tendency to lower the dose of these drugs (from 1500 to 600 mg daily) (4, 5) in an attempt to reduce side effects. The use of leupeptin and related peptides has never been clinically tested in the treatment of thromboembolic diseases. However, these compounds are currently under investigation for the treatment of muscular dystrophy in children. The synergism between protease and cyclooxygenase inhibitors described here may have important consequences in antiplatelet therapy; it may allow further reduction in the dose of cyclooxygenase inhibitors if given in combination with protease inhibitors. Furthermore, the inhibitory activity of leupeptin on thrombin-induced platelet activation may be useful when nonsteroidal antiinflammatory drugs alone are ineffective antithrombotic agents because they do not inhibit the thrombin-mediated pathway in thrombosis (1) .
